CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
Clofarabinedrug
Likely dose
Clofarabine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00299156
NCT00299156Phase 2Completed
CompareCT.gov

Phase II Study of Oral Clofarabine in Myelodysplastic Syndrome (MDS)

M.D. Anderson Cancer Center·interventional·Posted Mar 6, 2006·Updated Nov 3, 2015

In Brief

A Phase 2 clinical trial evaluating Clofarabine for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Completed, enrolled 65 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if clofarabine given by mouth on a weekly schedule can help to control MDS. The safety of clofarabine given by mouth will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
CountriesUnited States
CollaboratorsGenzyme, a Sanofi Company

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 6, 2006
Enrollment StartMar 1, 2006
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 20.3 years ago

Interventions

Clofarabinedrug

Starting dose 10 mg (Group 1) or 20 mg (Group 2) as tablets once a day for 5 days in a row and repeated every 4-8 weeks. Each 4-8 week period is a cycle.